Keyword: U.S. Department of Justice
A federal judge rebuffed Aegerion's proposed $36M marketing settlement, saying it highlights a "two-tier criminal justice system."
Transparency hasn't made much of a difference when it comes to drug and device makers' payments to doctors, which amounted to $2.6 billion last year.
Sanofi has ratcheted up the legal pressure on Mylan with a lawsuit claiming the EpiPen maker abused its monopoly position to “squelch” competition, including the French pharma's own Auvi-Q.
A U.S. judge has ordered Novartis to do something it’s been trying for a year to avoid: Hand over documents on 79K events the company says it held with doctors.
J&J has joined fellow drug giant Pfizer and a half-dozen smaller drugmakers in a Justice Department probe of patient-assistance charities.
Add Pfizer to the list of the companies facing a governmental investigation about its ties to copay assistance charities.
A new FDA rule that would govern off-label marketing has drugmakers in a minor tizzy—and they're demanding that the agency set its change aside.
Why didn't Medicaid officials go after Mylan for underpaying EpiPen rebates—and just how much did those years of underpayments cost the government?
Last week, U.S. federal authorities charged former Valeant exec Gary Tanner and former Philidor CEO Andrew Davenport with engineering a multimillion-dollar fraud and kickback scheme. But those charges may just be the beginning.
Federal prosecutors finally think they know what really happened between Valeant and the shadowy specialty pharmacy Philidor: They’re charging former execs from both companies for engineering a multimillion-dollar fraud and kickback scheme.